Skip to main content
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 2015 Jun 1;125(6):2547. doi: 10.1172/JCI82555

CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells

Andreas Herrmann 1, Saul J Priceman 1, Piotr Swiderski 2, Maciej Kujawski 1, Hong Xin 1, Gregory A Cherryholmes 1, Wang Zhang 1, Chunyan Zhang 1, Christoph Lahtz 1, Claudia Kowolik 3, Steve J Forman 4, Marcin Kortylewski 1, Hua Yu 1
PMCID: PMC4518694  PMID: 26030229

Original citation: J Clin Invest. 2014;124(7):2977–2987. doi:10.1172/JCI73174.

Citation for this corrigendum: J Clin Invest. 2015;125(6):2547. doi:10.1172/JCI82555.

In the original manuscript, Piotr Swiderski was omitted from the author list, and Steve J. Forman’s affiliation was incorrect. The correct author and affiliation lists are above. Supplemental Figure 1A included an incorrect sequence for the CTLA4-targeting aptamer and omitted the presence of an additional linker region. The figure and legend have been corrected and updated online to include additional information about the design of the CTLA4-targeting aptamer. A sentence regarding the Biopolymer Core was omitted from the Acknowledgments. The correct sentence is below.

We thank the staff of the Biopolymer Core at the Beckman Research Institute for designing and synthesizing the CTLA4apt–STAT3 siRNA conjugates.

The authors regret the errors.

Footnotes

See the related article beginning on page 2977.


Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES